VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Vancouver, BC (June 2, 2025) – Miata Metals Corp. (CSE: MMET) (FSE: 8NQ) (OTCQB:MMETF) (“Miata” or the “Company”) is pleased to announce that it has entered into an option agreement (the “Nassau Agreement”) with the registered owner (the “Optionor”) of the Nassau gold project in Suriname (“Nassau”), providing a path to increase the 70% interest currently held by the Company to 100%. “With this transaction, Miata now holds exposure to the potenti ...

Company Overview - Nexxen International Ltd. is a global advertising technology platform specializing in data and advanced TV, offering a flexible and unified technology stack that includes a demand-side platform (DSP) and supply-side platform (SSP) [3][4] - The company is headquartered in Israel and has offices across the United States, Canada, Europe, and Asia-Pacific, and is traded on Nasdaq under the ticker NEXN [4] Share Repurchase Program - In May 2025, Nexxen repurchased 1,260,000 Ordinary Shares at an average price of $11.30 [1] - As of May 31, 2025, the company had 59,483,096 Ordinary Shares outstanding and approximately $24.8 million remaining under its current share repurchase program authorization [2]

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) provides comments with respect to the announcement made on May 30, 2025 by the Minister of Energy and Mines of Andalucia, Mr. Jorge Paradela, that the Junta de Andalucia, through his ministry, has granted the exploitation license to Minera Los Frailes (“MLF”) to develop the Aznalcollar project. Spanish independent legal counsel of Emerita has reassured the Company that this a ...

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on its result for the first quarter of 2025 and its progress towards expansion objectives for the balance of the year. For the three months ended March 31, 2025 the Company realized revenues of $434,061 with a gross profit of $346,297. The Company recorded a comprehensive loss of $77,300 with a net increase in cash of $137,068. Plan the Work – Work the Plan The Company is cu ...

Press Release dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, today announces the successful completion of the sale of its stake in the Feed Enzymes Alliance to its partner Novonesis, a global leader in biosolutions, for €1.5 billion. The sale agreement was announced on February 11, 2025. dsm-firmenich received approximately €1.4 billi ...

Group 1 - Dow has signed a sale and purchase agreement to sell its 50% interest in DowAksa Advanced Composites Holdings BV to Aksa Akrilik Kimya Sanayii A.Ş. for expected proceeds of $125 million, reflecting an enterprise value of approximately 10x the estimated 2025 operating EBITDA [1][2] - The decision to exit the joint venture aligns with Dow's strategy to focus on core, high-value downstream businesses, and the proceeds will support the company's balanced capital allocation approach [2][4] - The sale is anticipated to close in the third quarter of 2025, pending customary regulatory approvals and other closing conditions [2] Group 2 - Dow is a leading materials science company with a focus on high-growth markets such as packaging, infrastructure, mobility, and consumer applications, delivering sales of approximately $43 billion in 2024 [3] - The company operates manufacturing sites in 30 countries and employs around 36,000 people, emphasizing its commitment to sustainability and profitable growth [3]

Core Insights - Regeneron Pharmaceuticals has entered into a strategic in-licensing agreement with Hansoh Pharmaceuticals to acquire exclusive rights for HS-20094, a dual GLP-1/GIP receptor agonist currently in Phase 3 testing in China [1][2] - The agreement includes an upfront payment of $80 million and potential additional payments of up to $1.93 billion based on development, regulatory, and sales milestones [2] - The acquisition aims to enhance Regeneron's pipeline focused on obesity treatments, addressing the quality of weight loss and associated long-term health benefits [3][5] Company Strategy - Regeneron is committed to improving obesity treatments by focusing on the quality of weight loss, aiming to sustain weight loss while preserving muscle mass [3][4] - The company plans to study combinations of HS-20094 with its proprietary drugs to address muscle loss and other obesity-related comorbidities such as cardiovascular diseases and diabetes [3][5] - Regeneron has a comprehensive pipeline targeting obesity and its related diseases, leveraging its scientific capabilities and clinical innovations [5][6] Clinical Development - HS-20094 has been studied in over 1,000 patients and is administered as a weekly subcutaneous injection, showing promising efficacy and safety data [1] - Ongoing clinical trials include a Phase 3 trial in obesity in China and a Phase 2b study in diabetes [1][3] - Regeneron is also conducting the Phase 2 COURAGE study, which investigates the addition of trevogrumab to semaglutide, with interim data announced recently [3]

~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington’s disease. Following recent Typ ...

Novonesis has successfully completed the acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025 (announcement No 2). Please read the full announcement in PDF. Attachment 2025_Closing_of_the_Feed_Enzyme_Alliance ...

– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – Virtual investor webcast today at 8:00 a.m. EDT – CUPERTINO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage p ...